HealthDay News — For Medicare beneficiaries after myocardial infarction (MI) hospitalization, statin intolerance is associated with increased risk of recurrent MI and coronary heart disease (CHD) events, according to a study published in the March 21 issue of the Journal of the American College of Cardiology.
Maria-Corina Serban, MD, PhD, from the University of Alabama at Birmingham, and colleagues studied 105,329 Medicare beneficiaries who began a moderate- or high-intensity statin dosage after MI hospitalization between 2007 and 2013.
The researchers found that, overall, 1.65% of patients had statin intolerance and 52.8% had high statin adherence. Statin intolerance correlated with a 36% higher rate of recurrent MI (41.1 versus 30.1 per 1,000 person-years), a 43% increased rate of CHD events (62.5 versus 43.8 per 1,000 person-years), and a 15% reduced rate of all-cause mortality (79.9 versus 94.2 per 1,000 person-years), compared to beneficiaries with high statin adherence. When comparing beneficiaries with statin intolerance to those with high statin adherence, the multivariate-adjusted hazard ratios were 1.50 (95% confidence interval [CI], 1.30 to 1.73), 1.51 (95% CI, 1.34 to 1.70), and 0.96 (95% CI, 0.87 to 1.06) for recurrent MI, CHD events, and all-cause mortality, respectively.
“Statin intolerance was associated with an increased risk for recurrent MI and CHD events but not all-cause mortality,” the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Amgen, which funded the study.